5:00 PM
 | 
Aug 05, 2013
 |  BC Extra  |  Top Story

MDCO acquires ProFibrix

The Medicines Co. (NASDAQ:MDCO) exercised its option to acquire all outstanding shares of hematology company ProFibrix B.V. (Leiden, the Netherlands) for $90 million in cash based on a review of data from the Phase III FINISH-3 trial evaluating ProFibrix's Fibrocaps...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >